Brand Name
Vivjoa
Generic Name
Oteseconazole
View Brand Information FDA approval date: July 11, 2022
Classification: Azole Antifungal
Form: Capsule
What is Vivjoa (Oteseconazole)?
VIVJOA™ is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis in females with a history of RVVC who are NOT of reproductive potential.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Platform Trial For Cryptococcal Meningitis
Summary: Cryptococcal meningitis is a fungal infection that causes a severe syndrome of meningitis that is 100% fatal without antifungal therapy. Even with antifungal therapy, mortality rates remain high, especially in low and middle income countries where the ongoing HIV/AIDS pandemic increases the risk of cryptococcosis among persons living with HIV infection. The combination of amphotericin and flucytos...